Hologic, Inc. (NASDAQ:HOLX) Director Christiana Stamoulis sold 13,257 shares of the business’s stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $44.50, for a total value of $589,936.50. Following the completion of the transaction, the director now owns 48,296 shares in the company, valued at approximately $2,149,172. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Christiana Stamoulis also recently made the following trade(s):
- On Tuesday, October 2nd, Christiana Stamoulis sold 30,967 shares of Hologic stock. The stock was sold at an average price of $40.70, for a total value of $1,260,356.90.
Shares of NASDAQ HOLX opened at $44.41 on Friday. Hologic, Inc. has a 52-week low of $35.10 and a 52-week high of $45.09. The company has a market cap of $12.84 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 2.05 and a beta of 0.65. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.95 and a current ratio of 1.23.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Piedmont Investment Advisors LLC acquired a new stake in Hologic during the second quarter valued at approximately $127,000. Bessemer Group Inc. raised its stake in Hologic by 122.4% during the third quarter. Bessemer Group Inc. now owns 3,534 shares of the medical equipment provider’s stock valued at $145,000 after buying an additional 1,945 shares in the last quarter. Amussen Hunsaker Associates LLC acquired a new stake in Hologic during the second quarter valued at approximately $159,000. Stratos Wealth Partners LTD. acquired a new stake in Hologic during the third quarter valued at approximately $185,000. Finally, Lincoln Capital Corp acquired a new stake in Hologic during the third quarter valued at approximately $201,000. Hedge funds and other institutional investors own 97.12% of the company’s stock.
Several research firms recently commented on HOLX. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Hologic in a research note on Thursday, September 27th. Canaccord Genuity cut their price target on Hologic from $42.00 to $41.00 and set a “hold” rating on the stock in a research note on Tuesday, August 14th. BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 25th. Morgan Stanley cut their price target on Hologic from $47.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 11th. Finally, UBS Group began coverage on Hologic in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $44.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $44.53.
TRADEMARK VIOLATION NOTICE: This article was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2018/12/02/christiana-stamoulis-sells-13257-shares-of-hologic-inc-holx-stock.html.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Read More: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.